Dual GIP and GLP-1 receptor agonist
Tirzepatide
The FDA label gives tirzepatide's elimination half-life as approximately 5 days, enabling once-weekly dosing.1
Tirzepatide after one dose: 50% at ~5 days, 25% at 10 days, 12.5% at 15 days.
Drawn from the half-life in the app's model, ~5 days. The model's figures
- Compound
- Tirzepatide
- Symbol
- TZ2
- Family
- GLP-1 and incretin
- Parts
- 15
- References
- 17
- Checked
- Last reviewed . Sources are listed below.
How Milligram users log it

5%The 12th most tracked compound in Milligram: of people who track compounds in Milligram logged Tirzepatide in the last 90 days.
Schedule
Logged doses
Half of people logged between 2.5 and 7.5 mg per dose; the median was 5 mg.
Tracked alongside
The share of people logging Tirzepatide who also logged each.
From dose logs in the Milligram app, 90 days to 15 November 2026. Aggregated and anonymous. This describes what people recorded, not what anyone should take.
Overview
Tirzepatide is a once-weekly GIP receptor and GLP-1 receptor agonist made by Eli Lilly and Company and sold in the United States as Mounjaro and Zepbound.1,2 The Mounjaro label lists two uses: glycemic control as an adjunct to diet and exercise in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus, and reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus at high risk for them.1 The Zepbound label lists two uses, each in combination with a reduced-calorie diet and increased physical activity: weight reduction and long-term maintenance of weight reduction in adults with obesity, or with overweight in the presence of at least one weight-related comorbid condition, and moderate to severe obstructive sleep apnea in adults with obesity.2
Both US labels give 2022 as the initial approval year, and the European Medicines Agency's product information gives 15 September 2022 as the date of first authorisation of Mounjaro.1,3 The app grades the evidence for tirzepatide as strong, and the phase 3 trials described below were funded or sponsored by Eli Lilly and Company, which makes both brands.
How it works
Sources in this part
The labels describe tirzepatide as a GIP receptor and GLP-1 receptor agonist that "selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1".1 The label states that it "enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner".1
Coskun and colleagues described the molecule in Molecular Metabolism in 2018 under the name LY3298176, which the SURPASS-2 registry entry lists as another name for tirzepatide.4,5 The paper lists 15 of its 16 authors at Eli Lilly and Company and one at Duke University Medical Center.4 Thirteen authors report being employees and shareholders of Eli Lilly and Company, two are former employees, and the Duke author "is a member of the Eli Lilly Scientific Advisory Board".4 In receptor binding studies, they report an affinity "comparable to native GIP for the GIPR and approximately 5-fold weaker than native GLP-1 for the GLP-1R".4 In mice given it chronically, they report that it "potently decreased body weight and food intake", and that these effects were "significantly greater than the effects of a GLP-1 receptor agonist".4
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~5 days
- Bioavailability
- 80%
- Typical dose
- 2.5–15 mg/week
- Route
- SubQ
- Time to peak
- ~24 h
Sources in this part
The figures in the second column of the table are the app's own, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | About 5 days (120 hours) | Elimination half-life of approximately 5 days on the US label and in the European product information; mean half-life 116.7 hours in a 2018 phase 1 study of 142 people (healthy volunteers and people with type 2 diabetes, 0.25 to 15 mg)1,3,4 |
| Bioavailability | 80% by subcutaneous injection | Mean absolute bioavailability of 80% after subcutaneous administration on the US label; 80% on the European product information1,3 |
| Time to peak | About 24 hours | Ranges from 8 to 72 hours on the US label and the European product information; the same phase 1 study of 142 people (healthy volunteers and people with type 2 diabetes, 0.25 to 15 mg) reports a maximum concentration within 24 to 48 hours of dosing1,3,4 |
The chart draws the app's one-compartment model with its half-life of 120 hours and time to peak of 24 hours, an illustration and not a measured level.1
Level over 6 weeks
Level, as a share of the peak after one 5 mg dose
As studied: every 7 days (once weekly)1. As logged in Milligram: the share of people with three or more logged doses on each schedule (How Milligram users log it).
An illustration from a pharmacokinetic model using a half-life of 120 hours (5 days). It is not a measured level or a suggested dose.
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Frías and colleagues, SURPASS-2, New England Journal of Medicine 20216 | Open-label phase 3 against semaglutide; funded by Eli Lilly | 1879 adults with type 2 diabetes taking metformin5 | Tirzepatide 5, 10 or 15 mg or semaglutide 1 mg once weekly; 40 weeks | HbA1c fell by 2.01, 2.24 and 2.30 percentage points on tirzepatide against 1.86 on semaglutide |
| Jastreboff and colleagues, SURMOUNT-1, New England Journal of Medicine 20227 | Double-blind, randomised, controlled phase 3; supported by Eli Lilly | 2539 adults with obesity, or overweight with a weight-related complication, excluding diabetes | Tirzepatide 5, 10 or 15 mg once weekly or placebo; 72 weeks | Week 72 weight change of -15.0%, -19.5% and -20.9% against -3.1% on placebo (treatment-regimen estimand) |
| Garvey and colleagues, SURMOUNT-2, Lancet 20238 | Double-blind, placebo-controlled phase 3; funded by Eli Lilly | 938 adults with a BMI of 27 or higher and type 2 diabetes (HbA1c 7 to 10%) | Tirzepatide 10 or 15 mg or placebo, once weekly; 72 weeks | Weight change of -12.8% and -14.7% against -3.2% with placebo (treatment-regimen estimand); serious adverse events in 68 (7%) overall and two deaths in the 10 mg group, not considered related to treatment by the investigator |
| Aronne and colleagues, SURMOUNT-4, JAMA 20249 | Randomised withdrawal after a 36-week open-label lead-in; sponsored by Eli Lilly, with six authors listed at Lilly | 783 adults entered the lead-in and 670 were randomised | Maximum tolerated dose (10 or 15 mg) for 36 weeks, then 335 continued tirzepatide and 335 switched to placebo for 52 weeks | Weight change from week 36 to week 88 of -5.5% with tirzepatide against +14.0% (a regain of lost weight) with placebo (difference -19.4%, 95% CI -21.2% to -17.7%) |
| Aronne and colleagues, SURMOUNT-5, New England Journal of Medicine 202510 | Open-label phase 3b against semaglutide; funded by Eli Lilly | 751 adults with obesity but without type 2 diabetes | Maximum tolerated dose of tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg) once weekly; 72 weeks | Weight change of -20.2% with tirzepatide against -13.7% with semaglutide at week 72 (P<0.001) |
| Malhotra and colleagues, SURMOUNT-OSA, New England Journal of Medicine 202411 | Two double-blind, randomised, controlled phase 3 trials; supported by Eli Lilly, with statistical analyses by sponsor employees | 469 adults (234 in trial 1, 235 in trial 2) with moderate-to-severe obstructive sleep apnea and obesity, without (trial 1) or with (trial 2) positive airway pressure therapy at baseline | Maximum tolerated dose of tirzepatide (10 or 15 mg) or placebo, once weekly; 52 weeks | Change in AHI at week 52 of -25.3 against -5.3 events per hour in trial 1 and -29.3 against -5.5 in trial 2 (estimated differences -20.0 and -23.8); no deaths in either trial |
| Packer and colleagues, SUMMIT, New England Journal of Medicine 202512 | International, double-blind, randomised, placebo-controlled trial; funded by Eli Lilly | 731 adults with heart failure, an ejection fraction of at least 50% and a BMI of at least 30 | Tirzepatide (up to 15 mg) or placebo, once weekly, for at least 52 weeks; median follow-up 104 weeks | Cardiovascular death or a worsening heart-failure event in 36 (9.9%) against 56 (15.3%) (hazard ratio 0.62, 95% CI 0.41 to 0.95); cardiovascular death alone in 8 against 5 (hazard ratio 1.58, 95% CI 0.52 to 4.83); adverse events leading to discontinuation in 23 (6.3%) against 5 (1.4%) |
| Nicholls and colleagues, SURPASS-CVOT, New England Journal of Medicine 202513 | Double-blind, active-comparator noninferiority trial; funded by Eli Lilly | 13,299 adults with type 2 diabetes and atherosclerotic cardiovascular disease randomised; 6586 tirzepatide and 6579 dulaglutide analysed | Tirzepatide (up to 15 mg) or dulaglutide (1.5 mg), once weekly | Primary composite (cardiovascular death, myocardial infarction or stroke) in 801 (12.2%) against 862 (13.1%) (hazard ratio 0.92, 95.3% CI 0.83 to 1.01; P=0.003 for noninferiority, P=0.09 for superiority); more gastrointestinal adverse events with tirzepatide |
The SURMOUNT-2 record lists authors at Eli Lilly and Company, Indianapolis.8 The SUMMIT record lists five authors (Weerakkody, Ou, Bunck, Hurt and Murakami) at Eli Lilly, and the SURPASS-CVOT record lists authors at Eli Lilly, Indianapolis.12,13 The authors' own limitation statements and disclosure statements for these three trials are not given here because the full text was not available.8,12,13
Deeper analysis: SURMOUNT-1
Jastreboff and colleagues reported SURMOUNT-1 in the New England Journal of Medicine in 2022.7 The affiliation list places five authors (N.N.A., S.Z., B.L., M.C.B. and A.S.) at Eli Lilly, Indianapolis.7 The trial assigned 2539 adults with a BMI of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, 1:1:1:1 to tirzepatide 5, 10 or 15 mg once weekly or placebo for 72 weeks, including a 20-week dose-escalation period.7 At week 72 the mean percentage change in weight was -15.0% with 5 mg, -19.5% with 10 mg and -20.9% with 15 mg, against -3.1% with placebo (P<0.001 for all comparisons).7 The authors report that the most common adverse events were gastrointestinal, "most were mild to moderate in severity", and that adverse events caused treatment discontinuation in 4.3%, 7.1% and 6.2% of the 5, 10 and 15 mg groups against 2.6% with placebo.7 The registry entry names Eli Lilly and Company as lead sponsor and posts a mixed-model primary result of -16.0, -21.4 and -22.5 against -2.4 on placebo, which differs from the journal's figures: the registry's analysis set excludes data after prematurely stopping study drug, whereas the journal's treatment-regimen estimand assesses effects regardless of treatment discontinuation.14,7 The journal record reads "Supported by Eli Lilly", and the authors' own limitation statements and disclosure statements are not given here because the full text was not available.7
Deeper analysis: SURPASS-2
Frías and colleagues reported SURPASS-2 in the New England Journal of Medicine in 2021.6 Five authors (L.F.L., B.K.B., B.L., X.C. and K.B.) are listed at Eli Lilly, Indianapolis.6 The trial was open-label, ran 40 weeks and randomly assigned 1879 patients 1:1:1:1 to tirzepatide 5, 10 or 15 mg or semaglutide 1 mg, with a primary end point of the change in glycated hemoglobin from baseline to 40 weeks.6 The estimated mean changes were -2.01, -2.24 and -2.30 percentage points with tirzepatide against -1.86 with semaglutide, with estimated differences of -0.15 (P=0.02), -0.39 and -0.45 (P<0.001 for both).6 The authors write that tirzepatide at all doses "was noninferior and superior to semaglutide", with greater weight reductions (P<0.001 for all comparisons).6 Nausea occurred in 17 to 22% of the tirzepatide groups and 18% with semaglutide, and serious adverse events in 5 to 7% against 3%.6 The registry entry names Eli Lilly and Company as lead sponsor, records no masking, and posts a primary result for the 10 and 15 mg groups of -2.37 and -2.46 against -1.86 with semaglutide, from an analysis set that excludes data after initiating rescue medication or prematurely stopping study drug.5 The journal record reads "Funded by Eli Lilly", and the authors' own limitation statements and disclosure statements are not given here because the full text was not available.6
Deeper analysis: SURMOUNT-4
Aronne and colleagues reported SURMOUNT-4 in JAMA in 2024, after online publication on 11 December 2023.9 Six authors are listed at Eli Lilly: Ahmad, Zhang, Liao, Bunck and Murphy in Indianapolis, who each report being an employee and shareholder of Eli Lilly and Company, and Jouravskaya in Moscow, for whom no statement is given.9 Five academic authors (Aronne, Sattar, Horn, Bays and Wharton) report grants, research funding, fees or nonfinancial support from Eli Lilly.9 The study "was sponsored by Eli Lilly and Company", which "was involved in the study design and conduct", the analyses, the interpretation of the data and the preparation of the manuscript.9 After the 36-week lead-in, which produced a mean weight reduction of 20.9%, 670 of 783 participants were randomised to continue tirzepatide (335) or switch to placebo (335) for 52 weeks.9 From week 36 to week 88 weight changed by -5.5% with tirzepatide and +14.0% with placebo (difference -19.4%, 95% CI -21.2% to -17.7%), and 89.5% against 16.6% kept at least 80% of the lead-in weight loss.9 Adverse events were mostly mild to moderate gastrointestinal events, more common with tirzepatide.9 The authors' own limitation statements are not given here because the full text was not available.9
Deeper analysis: SURMOUNT-5
Aronne and colleagues reported SURMOUNT-5 in the New England Journal of Medicine in 2025.10 Seven of the 11 authors in the journal record (Falcon, Gomez Valderas, Das, Lee, Glass, Senyucel and Dunn) are listed at Eli Lilly, Indianapolis.10 The phase 3b open-label trial randomly assigned 751 adults with obesity but without type 2 diabetes 1:1 to the maximum tolerated dose of tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg) once weekly for 72 weeks, with percent change in weight as the primary end point.10 The least-squares mean percent change in weight was -20.2% with tirzepatide and -13.7% with semaglutide (P<0.001), and participants on tirzepatide were more likely to have weight reductions of at least 10%, 15%, 20% and 25%.10 The registry entry names Eli Lilly and Company as lead sponsor, posts a between-group difference of -6.5 percentage points (95% CI -8.1 to -4.9) in an analysis set of 318 participants per arm, and lists no deaths among 374 tirzepatide and 376 semaglutide participants, serious adverse events in 18 and 13, and adverse events as the reason for stopping in 6 in each group.15 The journal record reads "Funded by Eli Lilly", and the authors' own limitation statements and disclosure statements are not given here because the full text was not available.10
Doses reported in studies and on labels
The app's typical dose of 2.5 to 15 mg per week runs from the labels' starting dosage to the labels' maximum dosage in adults.1,2 The Zepbound label states that the 2.5 mg dosage "is for treatment initiation and is not approved as a maintenance dosage".2
| Source | Population | Dose reported | Schedule and length |
|---|---|---|---|
| Mounjaro US label1 | Adults, and pediatric patients 10 years of age and older, with type 2 diabetes mellitus | Starting dosage 2.5 mg, with increases in 2.5 mg increments after at least 4 weeks on the current dose if additional glycemic control is needed; maximum 15 mg in adults and 10 mg in pediatric patients | Subcutaneous, once weekly |
| Zepbound US label2 | Adults with obesity or overweight with a comorbid condition; adults with obesity and moderate to severe obstructive sleep apnea | Starting dosage 2.5 mg for 4 weeks, then increases in 2.5 mg increments after at least 4 weeks; maintenance 5, 10 or 15 mg for weight reduction and 10 or 15 mg for sleep apnea; maximum 15 mg | Subcutaneous, once weekly |
Sources in this part
Side effects reported
The Zepbound label pools two placebo-controlled weight reduction trials (its Study 1 and Study 2) of 2,519 adults treated for up to 72 weeks.2 Across both trials, 4.8%, 6.3% and 6.7% of patients on 5, 10 and 15 mg permanently discontinued treatment because of adverse reactions, against 3.4% on placebo.2 The label's table lists 16 reactions at 2% or more and above placebo, and six are shown here.2
| Adverse reaction | Placebo (N=958) | 5 mg (N=630) | 10 mg (N=948) | 15 mg (N=941) |
|---|---|---|---|---|
| Nausea | 8% | 25% | 29% | 28% |
| Diarrhea | 8% | 19% | 21% | 23% |
| Vomiting | 2% | 8% | 11% | 13% |
| Constipation | 5% | 17% | 14% | 11% |
| Injection site reactions | 2% | 6% | 8% | 8% |
| Hair loss | 1% | 5% | 4% | 5% |
Sources in this part
The Zepbound label states that hair loss adverse reactions "were associated with weight reduction", and that hair loss was reported more frequently in female than male patients in the pool (7.1% against 0.5% on Zepbound, 1.3% against 0% on placebo).2
In the same pool, gastrointestinal adverse reactions occurred in 56% of each tirzepatide group against 30% with placebo, and 1.9%, 3.3% and 4.3% of the 5, 10 and 15 mg groups discontinued because of them against 0.5%.2 The label states that the majority of nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time.2 In the Mounjaro label's pool of placebo-controlled trials in adults with type 2 diabetes, gastrointestinal adverse reactions occurred in 37.1%, 39.6% and 43.6% of the 5, 10 and 15 mg groups against 20.4% with placebo, and discontinuation because of them was 3.0%, 5.4% and 6.6% against 0.4%.1
The Mounjaro boxed warning states that "In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures", and that it is unknown whether Mounjaro causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans.1 The label contraindicates it in patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, and in patients with known serious hypersensitivity to tirzepatide or any of the excipients.1 Its other warnings cover acute pancreatitis, hypoglycemia with insulin secretagogues or insulin, hypersensitivity reactions, acute kidney injury, severe gastrointestinal adverse reactions, diabetic retinopathy complications, acute gallbladder disease and pulmonary aspiration during anesthesia or sedation.1 In SURMOUNT-OSA, serious adverse events were reported by 35 participants (7.5%) overall, with similar percentages in both groups, including two adjudicated cases of acute pancreatitis in the trial 2 tirzepatide group and no medullary thyroid cancer.11
Bloodwork and markers
The app lists blood glucose, HbA1c and body weight as markers. HbA1c was the primary end point of the SURPASS-2 trial, and percentage weight change was a primary end point of SURMOUNT-1 and SURMOUNT-2.6,7,8 In its pharmacodynamics section, in the context of type 2 diabetes, the Mounjaro label reports that tirzepatide 15 mg reduced fasting glucagon concentration by 28% and glucagon AUC after a mixed meal by 43%, compared with no change for placebo after 28 weeks of treatment.1
Regulatory and anti-doping status
The European product information marks Mounjaro as a medicinal product subject to additional monitoring.3 FDA's page on unapproved GLP-1 drugs, current as of 1 October 2026, states that unapproved versions of drugs including tirzepatide "do not undergo FDA's review for safety, effectiveness and quality before they are marketed".16 It states that as of May 31, 2026 FDA had received more than 730 reports of adverse events associated with compounded tirzepatide, and that "It is not always possible to determine if the adverse event directly resulted from use of the drug or if other factors may have contributed to these adverse events".16 It also states that it is likely that adverse events from compounded versions "are underreported", and that "Many of the adverse events reported for compounded products appear to be consistent with adverse events related to the FDA-approved versions of these products".16 Tirzepatide is not named in the text of the World Anti-Doping Agency's 2026 Prohibited List.17
Storage and handling
Sources in this part
The Mounjaro label states that single-dose pens and vials are stored in a refrigerator at 2°C to 8°C (36°F to 46°F), and that each can be stored unrefrigerated at temperatures not to exceed 30°C (86°F) for up to a total of 21 days.1 The label lists single-dose pens and vials at 2.5, 5, 7.5, 10, 12.5 and 15 mg per 0.5 mL, and multi-dose vials and KwikPens, each holding four doses, from 10 mg/2.4 mL (4.17 mg/mL) to 60 mg/2.4 mL (25 mg/mL).1
What is not known
Sources in this part
The Mounjaro label states that the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.1 The SURMOUNT-OSA authors state that their trials did not investigate treatment longer than 52 weeks, and they name the ongoing SURMOUNT-Morbidity and Mortality in Obesity trial as one that "may provide additional information" on long-term cardiovascular outcomes.11 They also state that their trials excluded participants who did not have obesity and that trial 2 was not designed to investigate an effect of treatment on adherence to positive airway pressure treatment.11 The Mounjaro label states that available data in pregnant women are insufficient to evaluate for a drug-related risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes, and that, "Based on animal reproduction studies, there may be risks to the fetus from exposure to tirzepatide during pregnancy".1
Frequently asked questions
What is the half-life of tirzepatide?
How long does tirzepatide take to reach its peak level?
What is the bioavailability of tirzepatide?
How much weight did people lose on tirzepatide in trials?
In SURMOUNT-1 the mean weight change at week 72 was -15.0% with 5 mg, -19.5% with 10 mg and -20.9% with 15 mg, against -3.1% with placebo, in 2539 adults without diabetes (treatment-regimen estimand).7
How does tirzepatide compare with semaglutide in trials?
In SURMOUNT-5, an open-label trial in 751 adults with obesity, the weight change at week 72 was -20.2% with tirzepatide and -13.7% with semaglutide (P<0.001).10 In SURPASS-2, an open-label trial in 1879 adults with type 2 diabetes, HbA1c fell by 2.01, 2.24 and 2.30 points with tirzepatide against 1.86 with semaglutide; Eli Lilly funded both trials.6
What are the side effects of tirzepatide?
In the Zepbound label's pooled placebo-controlled weight reduction trials, nausea occurred in 25%, 29% and 28% of the 5, 10 and 15 mg groups against 8% with placebo, and diarrhea in 19%, 21% and 23% against 8%.2 The Mounjaro boxed warning concerns thyroid C-cell tumors in rats, with the human relevance not determined.1
Is tirzepatide FDA approved?
Is tirzepatide banned by WADA?
Tirzepatide is not named in the text of the World Anti-Doping Agency's 2026 Prohibited List.17 The list's class S0 covers any pharmacological substance not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use.17
Guides, tools and comparisons
- Tirzepatide dosageA guide that answers a question on this compound.
- Calculator for TirzepatideA calculator set up for this compound.
- Semaglutide vs tirzepatideA side-by-side with another compound.
- Retatrutide vs tirzepatideA side-by-side with another compound.
- Previous in GLP-1 and incretin: Teduglutide (GLP-2)The compound before this one in the class.
- Next in GLP-1 and incretin: CagrilintideThe compound after this one in the class.
References
- Eli Lilly and Company. Mounjaro (tirzepatide) injection, for subcutaneous use. US prescribing information, revised August 2026. DailyMed label
- Eli Lilly and Company. Zepbound (tirzepatide) injection, for subcutaneous use. US prescribing information, revised August 2026. DailyMed label
- European Medicines Agency. Mounjaro: summary of product characteristics (EPAR product information). EMA product information
- Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab 2018. PMC6308032
- ClinicalTrials.gov. NCT03987919: tirzepatide versus semaglutide once weekly as add-on therapy to metformin in patients with type 2 diabetes (SURPASS-2). Registry entry with posted results, record last updated 14 February 2022. NCT03987919
- Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 2021. PMID 34170647
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022. PMID 35658024
- Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023. PMID 37385275
- Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA 2024. PMC10714284
- Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med 2025. PMID 40353578
- Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med 2024. PMC11598664
- Packer M, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med 2025. PMID 39555826
- Nicholls SJ, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med 2025. PMID 41406444
- ClinicalTrials.gov. NCT04184622: tirzepatide once weekly in participants without type 2 diabetes who have obesity or are overweight (SURMOUNT-1). Registry entry with posted results, record last updated 24 July 2025. NCT04184622
- ClinicalTrials.gov. NCT05822830: tirzepatide compared with semaglutide in adults who have obesity or overweight with weight related comorbidities (SURMOUNT-5). Registry entry with posted results, record last updated 26 November 2025. NCT05822830
- US Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Page current as of 1 October 2026. FDA page
- World Anti-Doping Agency. The 2026 Prohibited List, International Standard. In force 1 January 2026. WADA 2026 list